Loading
6 slides generated from the front page, with a quiz from the open benchmark and speaker notes that cite the sources. Arrow keys move between slides; Print gives one slide per page.
Epigenetic and transcriptional therapy changes how genes are read rather than the genes themselves.
Epigenetic and transcriptional therapy changes how genes are read rather than the genes themselves. The section brings together DNMT and HDAC inhibitors used in haematological malignancies, EZH2 inhibitors, IDH inhibitors, menin inhibitors such as revumenib, BET inhibitors and emerging transcription-factor degraders, a class mostly established in blood cancers with solid tumours catching up. Linked records include the technologies epigenetic drugs and epigenetic editing, the term hypomethylating agents, the paper on the 2022 Hallmarks of Cancer, and the institutions USC Norris and Ruijin Hospital. Companies pointing here are Kura Oncology, Taiho Oncology, Servier, Syndax Pharmaceuticals, MorphoSys and Chipscreen Biosciences.